The effect of maternal soluble FMS-like tyrosine kinase 1 during pregnancy on risk of preterm delivery. (1/14)

 (+info)

Management of abnormal serum markers in the absence of aneuploidy or neural tube defects. (2/14)

 (+info)

Clinical utility of noninvasive fetal trisomy (NIFTY) test--early experience. (3/14)

 (+info)

Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. (4/14)

 (+info)

Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics. (5/14)

 (+info)

Noninvasive prenatal determination of twin zygosity by maternal plasma DNA analysis. (6/14)

 (+info)

Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. (7/14)

 (+info)

Feasibility study of semiconductor sequencing for noninvasive prenatal detection of fetal aneuploidy. (8/14)

 (+info)